Phase 2 Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 70 years old, of any sex
- People who have been diagnosed with type 2 diabetes
- People who are currently taking Ozempic (semaglutide injection) at a dose of at least 0.5 mg per week, along with lifestyle management and no more than 2 other blood sugar-lowering medications (metformin and/or an SGLT2 inhibitor), with all medication doses having been stable for at least 3 months before screening — if metformin is being taken, the dose must be at least 500 mg per day
- People whose HbA1c (a measure of average blood sugar over time) is between 7.5% and 9.5%
- People with a BMI between 25 and 40 kg/m²
- Women who could become pregnant must have a negative pregnancy test, must not be breastfeeding, and must agree to pregnancy testing and contraception requirements during the study
- People who are willing and able to sign a consent form and follow all study procedures
Who may not be able to join:
- People who have type 1 diabetes or a form of diabetes caused by another medical condition
- People who have had a serious diabetes-related emergency called diabetic ketoacidosis or hyperosmolar coma in the 6 months before screening
- People who have had a severe low blood sugar episode requiring another person's help to recover in the 6 months before screening, or who have difficulty recognising low blood sugar symptoms (as assessed by the trial doctor)
- People with a personal or family history (in a parent, sibling, or child) of certain rare hormonal conditions called MEN1 or MEN2, or a type of thyroid cancer called medullary thyroid carcinoma
- People who have used certain other blood sugar-lowering medications in the 3 months before screening — including GLP-1 medications other than Ozempic, dual GIP/GLP-1 medications, sulfonylureas, meglitinides, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, bile acid sequestrants, dopamine-2 agonists, amylin, or insulin (confirm with trial site if unsure which medications apply)
- People whose fasting blood sugar level is 240 mg/dL or higher at screening
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 8442450490
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic control
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.